Access to quality assured diagnostics and laboratory services is critical to the effective diagnosis, treatment, and management of HIV and other HIV-related diseases, including TB. Achieving an AIDS-Free Generation and the UNAIDS 90-90-90 targets requires establishment and operationalization of laboratory and diagnostic networks, including strong and sustainable collaborations with partners.To date, PEPFAR-supported laboratory and integrated diagnostic network strengthening efforts have led to improved access to the quality diagnostic and patient monitoring services required to support the HIV clinical cascade. However, work remains to establish and maintain the partnerships and collaborations required to support these efforts. This NOFO will focus on building and strengthening sustainable networks and partnerships to support laboratory systems, policies, and data use in PEPFAR-supported countries; improving in-service laboratory safety and science competencies through quality training for laboratory professionals; collaborations across partner organizations, laboratory professionals, and clinicians; strengthened public health laboratory and diagnostic network capacity, quality, and functionality; and improved access to high quality and effective technical assistance (TA) resources.
The goal of this NOFO is to provide comprehensive HIV services in Zambia to the general population in areas of high HIV prevalence; and priority populations (PPs), including people living with HIV (PLHIV), adolescent girls and young women (AGYW), men, couples, pregnant women, prisoners, and key populations (KPs). Services to be provided will include: community-based HIV testing services (HTS); HIV prevention services (risk reduction counseling,gender norms, and links to post gender-based violence (GBV) care); TB prevention and treatment, and community based antiretroviral therapy (ART). These services will be linked with community health care facilities. The recipient(s) will work closely with the relevant District Medical Offices (DMOs) selected in consultation with CDC Zambia. To ensure efficiencies and program effectiveness, this NOFO will support activities that complement activities supported by the Zambian government and partners with full transition to the local districts by the end of year five.
This NOFO will support achievement of national targets for 2018 antiretroviral therapy (ART) scale-up towards the UNAIDS Fast Track Targets in Ukraine. The recipient will implement innovative and effective recruitment and case management models for persons who inject drugs (PWID) and men who have sex with men (MSM) at the community level. These innovative changes will increase uptake of HIV community based testing and increase ART initiation for these populations. The recipient will pilot risk network-based testing using point-of-care recency assays to link recently infected PWID to care. The project will focus on the six regions with the highest HIV burden (Dnipropetrovsk, Mykolayiv, Odesa, government controlled areas (GCA) of Donetsk, Kyiv City, and Kherson) and continue to work in six additional medium burden oblasts (Cherkasy, Poltava, Chernihiv, Zaporizhzhya, Kirovohrad, and Kyiv). The recipient will also increase the capacity of the Government of Ukraine’s Center for Public Health (CPH) and regional monitoring and evaluation (M&E) centers specialists to conduct data analysis using statistical software and build institutional capacity to conduct economic evaluations of HIV interventions. Illustrative strategic information (SI) activities include development of trainings to support the Ministry of Health (MOH) and the newly established CPH in using statistical software, routine analysis of surveillance data, study design, and research protocol development.
This single-source funding opportunity announcement (FOA) Enhancing Public Health Emergency Preparedness and Response Capacities in the Americas in Collaboration with the National Center for Prevention Programs and Disease Control (CENAPRECE) in Mexico invites an application for a five-year cooperative agreement between the Department of Health and Human Services(HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) and the U.S.-Mexico Foundation for Science (FUMEC) to support CENAPRECE (an agency within Mexico Secretariat of Health [SALUD]). The envisioned ASPR-FUMEC-CENAPRECE collaboration sustains and advances the long-standing relationship between the United States and Mexico aimed at safeguarding each country from public health threats and fulfilling the goals of multiple international frameworks and agreements, including the International Health Regulations (2005) (IHR) (http://www.who.int/ihr/publications/9789241580496/en/). Projects and activities proposed by CENAPRECE for this agreement will combine strategic coordination of public health preparedness and emergency response programs as well as technical collaborations to strengthen the capacities of both countries and the region to prevent, detect, report, and respond to public health emergencies of all types, focusing on pandemic influenza, other emerging infectious diseases, and chemical, biological, and radiological (terrorism) hazards.
With PEPFAR support, CDC Haiti works in close collaboration with Haiti’s Ministry of Health (MSPP) to increase access to quality HIV clinical services, prevent mother-to-child transmission of HIV, and increase laboratory and strategic information capacity. In 2016, CDC Haiti adopted and implemented WHO’s Test and Start strategy, making treatment available to anyone who is HIV positive and reaching 80,000 people – over half of all people living with HIV in Haiti. The CDC program also led the development and implementation of key innovative approaches such as the biometric coding for unique patient identification and patient linkage and retention program. These interventions significantly improved the PEPFAR Haiti program performance. This NOFO aims to build upon these interventions and improve:Service delivery by providing technical assistance in the MSPP network to help strengthen HIV/AIDS-related services through clinical mentoring;Health workforce development by supporting both pre-service and in-service training efforts and working with MSPP in maintaining its national clinical guidelines; andHealth information systems by enhancing the iSanté Plus system, which includes patient care summaries, population-level data dashboards, automated program reports, epidemiological monitoring, and indicator reporting, and is linked to computerized lab results.
The purpose of this research is to identify, implement, and evaluate the use of effective strategies and tools for provider and patient use to taper and/or discontinue opioids, benzodiazepines, and other medications in which risk outweighs benefits to prevent falls, overdose, and other injuries among community dwelling older adults.
December 15, 2017, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Grants are made by the Board of Trustees of Ohio Cancer Research taking into account studies and recommendations of the Scientific Review Committee. Grants are available to investigators in either nonprofit or for-profit institutions, offices or clinics within the State of Ohio. However, grants to investigators working for profit-making organizations may not include funds for capital equipment. Grants are made with the stipulation of their use by a particular individual or group who are known as the principal investigator in support of a specific program of research under his/her/their direction.
Full professors or their equivalent are not eligible. Only tenure track, junior faculty or equivalent scientific staffs are generally considered as appropriate. Postdoctoral fellows, Research, research assistants, and graduate students are ineligible to apply as P.I.'s, but they may be included as support staff.
The P.I. must show evidence of independence. Applicants must be within six years of their first independent research or faculty appointment. Well established investigators should not submit projects related to their current area of research.
Investigators previously funded by Ohio Cancer Research must provide justification that this application is significantly different from the previously funded project. Information regarding the results of the previously funded proposal and the P.I.'s success in obtaining further national funding must also be provided.
Grants awarded by Ohio Cancer Research are made to support research activities broadly related to cancer and leukemia. Certain types of projects are not recommended for support. Among these are purely clinical work of a non-research nature and requests for the sole purpose of equipping a laboratory.
The purpose of the SCRI program is to address the critical needs of the specialty crop industry by awarding grants to support research and extension that address key challenges of national, regional, and multi-state importance in sustaining all components of food and agriculture, including conventional and organic food production systems.
The goal of this funding opportunity announcement (FOA) is to translate and adapt the most successful global, evidence-based HIV-related service provision strategies to marginalized populations in the United States (U.S.) with a substantial risk of HIV-infection and AIDS. The ultimate goal, is to produce improvements in HIV-related health outcomes in these key populations through strategies that successfully and durably reach them with timely HIV testing, prevention and treatment technologies that lead to the achievement of the UNAIDS 90-90-90 benchmarks: by 2020, 90 percent of all people living with HIV will know their HIV status, 90 percent of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90 percent of all people receiving antiretroviral therapy will have viral suppression.
Career Development Award supports early-career, independent investigators to conduct impactful research under the mentorship of an experienced lung cancer researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of lung cancer research. This award is intended to support impactful research projects with an emphasis on discovery. Submissions from and partnerships with investigators at military treatment facilities, military labs, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged.Preliminary data are not required. However, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated.Key elements of this award are as follows.
The Epilepsy Foundation has announced its seventh annual epilepsy "Shark Tank" competition for the most innovative ideas in epilepsy and seizure treatment and care.
Some examples of novel ideas include a system to detect seizures with the capacity to provide early warning to the patient or family; a treatment that stops a seizure from progressing; a system that helps patients manage their daily treatment; a device that prevents physical injury that patients may experience when in seizure; or an entirely new product concept with the promise to dramatically improve the lives of people with epilepsy.
Selected finalists will receive international recognition and compete for grants totaling $150,000 to support the development and commercialization of important new products, technologies, or therapeutic concepts.
As many as six finalists will be selected to present at the 2018 Epilepsy Pipeline Conference (San Francisco, February 22-23, 2018). Each presenter will have five minutes to present the concept, followed by five minutes of questioning. The Shark Tank event will feature live voting among audience members and a panel of judges (Sharks) representative of industry, advocacy, investors, and the research and medical communities. The winning project, or projects, deemed to be the most innovative will be announced at the conclusion of the competition.
To be eligible, applicants must demonstrate an ability to move the proposed plan to completion, showing how the prize can accelerate any step along the path to market. Inventors who submitted ideas for previous Shark Tank competitions are encouraged to re-submit their ideas if substantial progress has been made.
The MBRP Clinical Trial Award mechanism is being offered for the first time in FY17.The objective of this Program Announcement is to explore innovative approaches to accelerate the translation of knowledge advances into new treatments for the Service members who sustain burn injuries. The results of the research funded through the FY17/18 MBRP Clinical Trial Award are expected to increase the body of knowledge and materiel products available to professionals and practitioners in health, medical science, and related fields. The research impact is expected to benefit both civilian and military communities.The FY17/18 MBRP Clinical Trial Award supports clinical research studies with the potential to have a major impact on the prevention, treatment, and mitigation of debilitating burn scars that are relevant to military personnel. The specific intent is to improve functional outcomes and/or assess clinical efficacy and safety of different treatment modalities (e.g., dressing topics, biologics, cell-based therapies, mechanical, photonics).
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support screening of target-based pharmaceutical libraries to identify candidate therapeutics against select eukaryotic pathogens and subsequent preclinical development activities.
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Institute of Mental Health (NIMH) R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs and advance the priorities outlined in the Office of AIDS Research (OAR) Annual Strategic Plan and the research program priorities of the NIMH Division of AIDS Research (DAR).
To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences and Mentoring Activities that either capitalize on existing networks of collaborating investigators or develop institute-based research education programs. Both research experiences and mentoring activities are required; research experiences are expected to be primary. Research Education Programs are expected to enhance the professional development of the participants and foster a career trajectory towards independent research in the mental health of HIV/AIDS.
This NOFO builds upon the achievements so far made in strengthening the health systems ability to achieve HIV epidemic control in Ethiopia and supports the implementation of comprehensive HIV/AIDS programs in the four emerging regions focusing on priority scale-up and sustained sub-national units (SNUs). The recipient will also provide technical assistance (TA) to the Federal Ministry of Health (FMOH) and seven Regional Health Bureaus (RHBs) having direct awards with CDC - including two city administrations - and other government organizations as appropriate, with the ultimate goal of strengthening local ownership and attaining the UNAIDS 90-90-90 goals for epidemic control of HIV/AIDS. The recipient will ensure that adequate capacity is built at the RHB and lower SNU levels for a gradual transition of activities considered to be matured, including site-level activities implemented in the four emerging regions. The nature of TA during the 5 year project period may change depending on program dynamics and readiness of organizations in the emerging regions as well as TA recipients. The recipient will also be engaged in planning and rolling-out support of new US and host government initiatives and interventions developed to improve performance and achieve targets set to achieve epidemic control in top priority SNUs.
This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.
The goal of this funding opportunity announcement is to continue and expand the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium and enable data-driven discovery and validation of novel targets and biomarkers for AD and AD-related dementias through the development of predictive network models of brain health and disease.
The goal of this funding opportunity announcement is to solicit applications focused on 1) providing data enablement for the open-science, systems-biology enterprise of the AMP-AD Target Discovery and Preclinical Validation Consortium supported through the companion FOA (RFA-AG-18-013) and 2) sustaining and expanding the big-data infrastructure of the AMP-AD Knowledge Portal as a collaborative research platform through which members of the Consortium, researchers at large, and citizen scientists can engage in rapid translational learning and contribute to the development of predictive models of AD and AD-related dementias.
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.
